Leticia Castrillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leticia Castrillo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Salazar-Rodríguez
Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic, 08036 Barcelona, Spain
2 shared publications - Juan José Rodríguez-Arias
Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic, 08036 Barcelona, Spain
2 shared publications - Luis Ortega-Paz
Division of Cardiology, College of Medicine, University of Florida, Jacksonville, FL 32206, USA
2 shared publications - Manel Sabaté
Interventional Cardiology Department, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain (M.S.).
2 shared publications - Margarita Calvo-López
Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic, 08036 Barcelona, Spain
2 shared publications - Mercè Roqué
Servicio de Cardiología, Hospital Clínic, Universidad de Barcelona e Instituto de Investigaciones Biomédicas August Pi i Sunyer - IDIBAPS, Barcelona, España
2 shared publications
Latest Publications
- Open Access
- 9 December 2022
- Published by Springer Nature in Research Square
Antithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet Regimens
BACKGROUND: Treatment with triple antithrombotic therapies increases bleeding risks. AIM: We evaluated the antithrombotic and prohemorrhagic actions of different concentrations of apixaban (APIX) in healthy donors and patients exposed to currently used antiplatelet regimens. METHODS: 25 healthy subjects and 53 patients treated with aspirin (ASA, n=21), ASA and clopidogrel (ASA+CLOPI, n=11), or ASA and ticagrelor (ASA+TICA, n=21) participated in the study. Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on 1) clot formation, by ROTEM thromboelastometry; 2) thrombin generation primed by platelets; and 3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. RESULTS: APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160 and moderately affected by the antiplatelets, with ASA+TICA actions being the strongest among them (pCONCLUSIONS: APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but appears more conservative for hemostasis than the concentrations of 160 ng/mL that corresponds to the Cmax reached after the standard dose for thromboprophylaxis.
- 9 December 2022
- Published by Springer Nature in Research Square
Open AccessAntithrombotic and Prohemorrhagic Actions of Different Concentrations of Apixaban in Patients Exposed to Single and Dual Antiplatelet Regimens
BACKGROUND: Treatment with triple antithrombotic therapies increases bleeding risks. AIM: We evaluated the antithrombotic and prohemorrhagic actions of different concentrations of apixaban (APIX) in healthy donors and patients exposed to currently used antiplatelet regimens. METHODS: 25 healthy subjects and 53 patients treated with aspirin (ASA, n=21), ASA and clopidogrel (ASA+CLOPI, n=11), or ASA and ticagrelor (ASA+TICA, n=21) participated in the study. Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on 1) clot formation, by ROTEM thromboelastometry; 2) thrombin generation primed by platelets; and 3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. RESULTS: APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160 and moderately affected by the antiplatelets, with ASA+TICA actions being the strongest among them (pCONCLUSIONS: APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but appears more conservative for hemostasis than the concentrations of 160 ng/mL that corresponds to the Cmax reached after the standard dose for thromboprophylaxis.
- Open Access
- 5 October 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (10) , 128
Acute and Chronic Effects of COVID-19 on the Cardiovascular System
COVID-19 has shown significant morbidity with the involvement of multiple systems, including the cardiovascular system. Cardiovascular manifestations in the acute phase can include myocardial injury itself, myocardial infarction, venous thromboembolic events, myocarditis, Takotsubo syndrome, and different arrhythmic events. Myocardial injury defined by the rise of cardiac biomarkers in blood has been found in multiple studies with a prevalence of about 20%. Its presence is related to worse clinical outcomes and in-hospital mortality. The mechanisms of myocardial injury have been the subject of intense research but still need to be clarified. The characterization of the cardiac affectation with echocardiography and cardiac magnetic resonance has found mixed results in different studies, with a striking incidence of imaging criteria for myocarditis. Regarding post-acute and chronic follow-up results, the persistence of symptoms and imaging changes in recovered COVID-19 patients has raised concerns about the duration and the possible significance of these findings. Even though the knowledge about this disease has increased incredibly in the last year, many aspects are still unclear and warrant further research.
- 5 October 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (10) , 128
Open AccessAcute and Chronic Effects of COVID-19 on the Cardiovascular System
COVID-19 has shown significant morbidity with the involvement of multiple systems, including the cardiovascular system. Cardiovascular manifestations in the acute phase can include myocardial injury itself, myocardial infarction, venous thromboembolic events, myocarditis, Takotsubo syndrome, and different arrhythmic events. Myocardial injury defined by the rise of cardiac biomarkers in blood has been found in multiple studies with a prevalence of about 20%. Its presence is related to worse clinical outcomes and in-hospital mortality. The mechanisms of myocardial injury have been the subject of intense research but still need to be clarified. The characterization of the cardiac affectation with echocardiography and cardiac magnetic resonance has found mixed results in different studies, with a striking incidence of imaging criteria for myocarditis. Regarding post-acute and chronic follow-up results, the persistence of symptoms and imaging changes in recovered COVID-19 patients has raised concerns about the duration and the possible significance of these findings. Even though the knowledge about this disease has increased incredibly in the last year, many aspects are still unclear and warrant further research.
- Open Access
- 13 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2096
Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis
The exact mechanisms leading to myocardial injury in the coronavirus disease 2019 (COVID-19) are still unknown. In this retrospective observational study, we include all consecutive COVID-19 patients admitted to our center. They were divided into two groups according to the presence of myocardial injury. Clinical variables, Charlson Comorbidity Index (CCI), C-reactive protein (CRP), CAC (COVID-19-associated coagulopathy), defined according to the ISTH score, treatment and in-hospital events were collected. Between March and April 2020, 331 COVID-19 patients were enrolled, 72 of them (21.8%) with myocardial injury. Patients with myocardial injury showed a higher CCI score (median (interquartile range), 5 (4–7) vs. 2 (1–4), p = 0.001), higher CRP values (18.3 (9.6–25.9) mg/dL vs. 12.0 (5.4–19.4) mg/dL, p ˂ 0.001) and CAC score (1 (0–2) vs. 0 (0–1), p = 0.001), and had lower use of any anticoagulant (57 patients (82.6%) vs. 229 patients (90.9%), p = 0.078), than those without. In the adjusted logistic regression, CRP, myocardial injury, CCI and CAC score were positive independent predictors of mortality, whereas anticoagulants resulted as a protective factor. Myocardial injury in COVID-19 patients is associated with inflammation and coagulopathy, resulting in a worse in-hospital prognosis. Treatment with anticoagulant agents may help to improve in-hospital outcomes.
- 13 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2096
Open AccessMyocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis
The exact mechanisms leading to myocardial injury in the coronavirus disease 2019 (COVID-19) are still unknown. In this retrospective observational study, we include all consecutive COVID-19 patients admitted to our center. They were divided into two groups according to the presence of myocardial injury. Clinical variables, Charlson Comorbidity Index (CCI), C-reactive protein (CRP), CAC (COVID-19-associated coagulopathy), defined according to the ISTH score, treatment and in-hospital events were collected. Between March and April 2020, 331 COVID-19 patients were enrolled, 72 of them (21.8%) with myocardial injury. Patients with myocardial injury showed a higher CCI score (median (interquartile range), 5 (4–7) vs. 2 (1–4), p = 0.001), higher CRP values (18.3 (9.6–25.9) mg/dL vs. 12.0 (5.4–19.4) mg/dL, p ˂ 0.001) and CAC score (1 (0–2) vs. 0 (0–1), p = 0.001), and had lower use of any anticoagulant (57 patients (82.6%) vs. 229 patients (90.9%), p = 0.078), than those without. In the adjusted logistic regression, CRP, myocardial injury, CCI and CAC score were positive independent predictors of mortality, whereas anticoagulants resulted as a protective factor. Myocardial injury in COVID-19 patients is associated with inflammation and coagulopathy, resulting in a worse in-hospital prognosis. Treatment with anticoagulant agents may help to improve in-hospital outcomes.